MRK merck.com: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Merck & Co. - graphic logo of issuer MRK

Production robotization and AI-driven compound analysis are increasing the profitability of Merck & Co., Inc. (MRK). The company's trend EV/EBITDA level demonstrates the current business value relative to operating income, where the 21.23 indicator expresses the state of the metric. An elite scientific staff ensures breakthroughs in vaccination, while the monopoly status of oncology drugs guarantees pricing power despite US regulatory risks.

Merck & Co. - MRK Enterprise Value to Operating Income Before Depreciation (period 11/23/2025 - 11/10/2026)

merck.com - analytical breakdowns and key metrics (MRK)

- market price and analyst price targets:
Price Chart Merck Sharp & Dohme|MRK - Average Forecast Price
- company stock capitalization data:
Market Value MSD|MRK - Total Company Value
- book value of equity indicators:
Book Value per Share Merck|MRK - Accounting Capitalization|Market Capitalization to Book Value Ratio merck.com|MRK - Company Total Asset Base
- business debt structure and liquidity details:
Debt to Equity Merck & Co., Inc.|MRK - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Merck|MRK - Company Total Indebtedness|Debt to Book Capitalization Ratio MSD|MRK - Company Long-Term Liabilities|Company Short-Term Debts Merck|Quick Liquidity merck.com
- financial results and valuation multiples details:
MRK - Final Profit|Projected Future Earnings Merck & Co., Inc.|MRK - Price to Earnings Ratio|Future Price to Earnings Merck & Co., Inc.|MRK - PEG Multiple|Enterprise Value to EBITDA Ratio MSD|MRK - Income before deduction of interest, taxes and amortization|Earnings per share for the last 12 months Merck|MRK - Earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months merck.com|MRK - Earnings per share increase in current year|Earnings growth forecast for next year Merck & Co., Inc.
Basic company analysis:MRK (Merck Sharp & Dohme)
Original product of merck.com

EV/EBITDA determines the value of a business relative to its operating profit before depreciation, interest, and taxes. The metric aggregates market capitalization and net debt, allowing for an assessment of the asset's real price regardless of the financing structure. Analyzing the EV/EBITDA ratio of Merck & Co., Inc. (MRK) helps identify asset undervaluation during periods of volatility. This is critical for Merck & Co., Inc. (MRK) amid large-scale investments in environmental modernization and the transition to green energy.

Competitors of Merck & Co., Inc. (MRK)

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Eli Lilly & Co. LLY|AbbVie Corp. (ABBV) - Company Value to EBITDA|AZN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NVS: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NVO: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation AMGN|PFE (Pfizer Corporation) - EV/EBITDA Multiple|Sanofi Group (SNY) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bristol-Myers Squibb (BMY)|gsk.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple TAK (Takeda)|Enterprise Value to EBITDA Multiple Teva Pharma|RDY - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Mylan (VTRS) - Enterprise Value to EBITDA Ratio|ROIV: EV/EBITDA Multiple|Company Value to EBITDA zailaboratory.com (ZLAB)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bausch Health|COSM: Business Value to Operating Income Before Depreciation